“Constantly innovating to improve patients’ quality of life, that is what sets us apart.”
President of Servier
Discover Servier
Unleash hope
Summary
01
Windows on our times
1.1
How AI is transforming pharmaceutical research
1.3
Adherence to treatment : when every pill matters
1.4
A healthy environment, fundamental to human health
A healthy environment, fundamental to human health
02
All about Servier
2.1
Presence throughout the world
2.3
Pipeline and therapeutic areas
2.5
Ethics and compliance at the heart of the Group
2.6
Our model for value creation
2.8
Servier 2030: laying the foundations for future success
Servier 2030: laying the foundations for future success
2.9
Meeting the expectations of our stakeholders
2.10
Making an impact in society to benefit patients and bring about a more sustainable world
Making an impact in society to benefit patients and bring about a more sustainable world
03
Our results
3.1
Financial results
3.2
Non-financial results
EDITORIAL
2023-2024
STANDOUT ACHIEVEMENTS
October 2023
A partnership signed with Owkin
This multi-year agreement will enable us to associate Owkin’s cutting-edge artificial intelligence technology with a multitude of clinical data to develop new targeted treatments in a range of therapeutic areas. We will also enhance our understanding of the underlying biology of illnesses in order to identify patient populations that are most likely to benefit from certain treatments.
New authorization in oncology in the US
The Food and Drug Administration (FDA) approved one of our treatments for myelodysplastic syndromes.
JAnuary 2024
A community center opened in Turkey
With support from Mécénat Servier, a community center spanning 434 m² was built in Kahramanmaraş after earthquakes devastated the region. The organization will help dozens of female entrepreneurs to launch their own business through the KIGEM program, in collaboration with the United Nations Development Programme (UNDP) and the local chamber of commerce and industry.
434 m²
The surface area of the community center supported by Mécénat Servier in Kahramanmaraş.
MARch 2024
Engaged employees!
Across all our subsidiaries, our employees demonstrate the collective commitment that earned us the Gallup Exceptional Workplace Award in 2024.
Servier received the Gallup Exceptional Workplace Award, which recognizes the companies with the highest level of employee engagement, achieving a rating 11 times above the global average. We were the first company in France to earn such a distinction. Moreover, our annual engagement survey calculated a score of 4.33/5 for 91% of people surveyed, which is up on last year.
60
To date, only 60 companies around the world have received the Gallup Exceptional Workplace Award!
CHINA
ACCELERATING IN ONCOLOGY
dECEMBER 2023
Servier acquired the exclusive rights from CStone to develop and market an oncology medicine in Greater China and Singapore. The agreement means Servier now owns the global rights to this treatment.
FEBrUARY 2024
In late 2022, Servier obtained approval to market a treatment for pancreatic cancer in the US, the first treatment of its kind authorized for 23 years. An assistance program offers financial support to low-income patients, in collaboration with China Primary Healthcare. In February 2024, 257 patients had already begun receiving treatment.
JUNE 2024
We signed a partnership with AmoyDx, a visionary molecular diagnostic company based in China, to develop a companion diagnostic test to detect certain gene mutations in diffuse glioma.
MAy 2024
Egis recognized
for its SPC
Egis, our Hungarian generics subsidiary, won the Hungarian Innovation Grand Prize for developing two Single Pill Combinations (SPC).
Progress in the fight against pancreatic cancer
The European Commission granted Servier the authorization to market a first-line treatment for patients living with pancreatic cancer.
JUNe 2024
THRPTX in Saclay, France
Servier organized THRPTX, its first international scientific symposium. Designed to serve as a catalyst to channel global scientific excellence to drive progress in research, the event brought together 200 eminent experts, professionals, researchers and decision-makers from all over the world. It was held under the patronage of William G. Kaelin Jr., who won the Nobel Prize in Physiology or Medicine in 2019.
In 2024, Servier celebrated its 70th anniversary!
70th !
Engagement with and for patients recognized once again!
The PatientView Report once again ranked Servier within the Top 3 companies for the reputation of pharmaceutical companies working with oncology patient organizations. For the first time, Servier came out top in three categories: “Transparency on Data”, “Beyond the Pill”, and “R&D”. In the US, we led the rankings in 12 out of 14 categories compiled by US-based patient organizations that know the Servier Group. We were the first laboratory in France to earn such a distinction.
August 2024
A new brain cancer treatment approved
The Food and Drug Administration approved the treatment developed by Servier for adults and children over the age of 12 with a form of brain cancer.
New study into hypertension
At the 2024 European Society of Cardiology Congress, we presented the findings of a study into a Single Pill Combination containing four molecules to treat hypertension.
2nd
Our ranking in the 2025 global HappyIndex® Trainees.
OCTOBer 2024
Servier certified HappyIndex® Trainees 2025
For the third consecutive year, our Group was ranked second in the Happy Trainee ranking of companies all around the world based on the experience they offer students (including interns, work/study students, VIE international volunteers, and post-doctoral students). For the first time, Servier came out as the top company in France.